Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54gp140 + GLA-AF (Imperial College London, b372ab)
- Development stage
- Phase 1
- Lead developer
- Imperial College London
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CN54gp140 + GLA-AF is a prophylactic HIV-1 vaccine candidate developed by Imperial College London. It consists of a recombinant, trimeric HIV-1 clade C envelope glycoprotein (CN54gp140) formulated with the synthetic Toll-like receptor 4 (TLR4) agonist adjuvant, glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF). The vaccine is designed to elicit both humoral and cellular immune responses against the HIV-1 envelope protein to provide protection against HIV infection. It has been evaluated in Phase 1 clinical trials to assess safety and immunogenicity in healthy, HIV-uninfected volunteers, often as part of prime-boost regimens involving DNA plasmids or viral vectors.
- Other names
- CN54gp140 HIV vaccineCN-54gp140 HIV vaccineCN 54gp140 HIV vaccineCN54gp140/GLA-AF
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)LY96 (Myeloid differentiation factor 2)TLR4 (Toll-like receptor 4)gp140 (HIV-1 gp140)
Beyond the preview
Go deeper on CN54gp140 + GLA-AF (Imperial College London, b372ab).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54gp140 + GLA-AF (Imperial College London, b372ab).